Drug-Induced Nail Disorders
- First Online:
- 112 Downloads
A large number of drugs of different classes, ranging from antibacterials to chemotherapeutic agents to psoralens, can be responsible for the development of nail changes. Drug-induced nail changes usually involve several or all 20 nails and appear in temporal correlation with drug intake. Some nail changes are asymptomatic and only cause cosmetic problems, while others cause pain and discomfort and impair manual activities or deambulation. Drug-induced nail abnormalities are usually transitory and disappear with drug withdrawal, but sometimes persist in time.
The pathogenesis of the nail changes is usually a toxic effect of the drug on the different nail constituents, but other mechanisms can be involved.
Drugs that are well known to produce nail abnormalities include cancer chemotherapeutic agents, psoralens, retinoids, tetracyclines, antimalarials and zidovudine. Arsenic poisoning is also always associated with nail changes that have medico-legal importance.
Some drugs taken during pregnancy may impair nail development of the fetus, and nail hypoplasia or other nail dystrophies will be evident in the newborn.
Unable to display preview. Download preview PDF.
- 1.Zaias N. The nail in health and disease. 2nd rev. ed. Norwalk: Appleton & Lange, 1990Google Scholar
- 2.Tosti A, Baran R, Dawber RPR. The nail in systemic diseases and drug-induced changes. In: Baran R, Dawber RPR, editors. Diseases of the nails and their management. 2nd ed. Oxford: Blackwell Scientific Publications, 1994: 175–261Google Scholar
- 4.Baran R, Dawber R, Haneke E, et al. A text atlas of nail disorders. London: Martin Dunitz, 1996Google Scholar
- 8.Baran R, Témime P. Les onychodystrophies toxi-medicament-euses et les onycholyses. Concours Med 1973; 95: 1007–23Google Scholar
- 11.Miller E. Levodopa and nail growth. N Engl J Med 1973; 208: 916Google Scholar
- 15.Knight JF. Side benefits of the pill [letter]. Med J Aust 1974; Nov: 680Google Scholar
- 33.Huinink WWB, Prove AM, Piccart M, et al. A phase II trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527–32Google Scholar
- 35.Varotti C, Ghetti E, Piraccini BM, et al. Subungual hematomas in a patient treated with an oral anticoagulant (warfarin sodium). Eur J Dermatol 1997; 7: 395–6Google Scholar
- 36.Vogelzang JN, Bosl GJ, Johnson K, et al. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Annlnt Med 1981; 95: 288–92Google Scholar
- 39.Tosti A, Piraccini BM, Baran R. The melanocyte system of the nails and its disorders. In: Nordlund JJ, Boissy RE, Hearing VJ, et al, editors. The pigmentary system. New York: Oxford University Press, 1998; 937–43Google Scholar
- 43.Urabe K, Nakayama J, Hori Y. Mixed epidermal and dermal hypermalanosis. In: Nordlund JJ, Boissy RE, Hearing VJ, et al, editors. The pigmentary system. New York: Oxford University Press, 1998; 909–35Google Scholar
- 45.Tosti A, Piraccini BM, Guerra L, et al. Reversible melanonychia due to clofazimine [abstract no.183 A]. 18th World Congress of Dermatology; 1992 Jun 12–18; New York, 183Google Scholar